EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Incidence, Prevalence, Hospitalization Rates, and Treatment Patterns in Myasthenia Gravis: A 10-Year Real-World Data Analysis of German Claims Data

Hannes Wartmann, Sarah Hoffmann, Tobias Ruck, Christopher Nelke, Barthold Deiters, Timm Volmer

Neuroepidemiology · 2023

DOI: 10.1159/000529583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuroepidemiology, 2023. Verfasst von Hannes Wartmann und 5 weiteren Autor:innen. Beteiligte Einrichtung: SmartStep Data Institute GmbH, Hamburg, Germany, wartmann@smartstep-data-institute.de. Hauptthemen laut MEDLINE: COVID-19, Myasthenia Gravis. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myasthenia gravis (MG) is a rare chronic autoimmune disease caused by autoantibodies directed against postsynaptic antigens of the neuromuscular junction. Over the last decades, increasing incidence and prevalence rates have been reported. Epidemiological data on prevalence and incidence in Germany are lacking. Furthermore, the MG treatment landscape is rapidly changing due to the continued approval of novel monoclonal antibodies.

Method

This is a retrospective study assessing incidence, prevalence, and hospitalization rates of MG as well as treatment patterns in Germany over 10 years based on medical claims data covering 6.1 million insured persons.

Results

Between 2011 and 2020, the prevalence rate of MG increased from 15.7 to 28.2 per 100,000 person-years. The age-adjusted incidence rate was 2.8 per 100,000 person-years within the study period (95% confidence interval, 2.43–3.22) and decreased dramatically in 2020, the year of the COVID-19 pandemic. Similarly, the hospitalization rate fluctuated within the study period but reached an overall low of 8.3% in 2020 (mean hospitalization rate 11.5%). Treatment patterns showed that most MG patients are treated with base therapy. However, crisis intervention is necessary for 2–5% of MG patients, and therapeutic monoclonal antibodies, including rituximab and eculizumab, are increasingly used.

Conclusion

This is the first study on MG prevalence and incidence rates in Germany. Data show an increase in prevalence by 1.8-fold over 10 years. Decreasing incidence and hospitalization rates in 2020 hint at the impact of the COVID-19 pandemic. Treatment patterns in MG are changing with the advent of therapeutic monoclonal antibodies in this indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Myasthenia GravisHumansIncidenceRetrospective StudiesPrevalencePandemicsAntibodies, MonoclonalData Analysis

Stichwörter der Autor:innen

Claims data analysisIncidenceMyasthenia gravisPrevalenceTreatment patterns

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • SmartStep Data Institute GmbH, Hamburg, Germany, wartmann@smartstep-data-institute.de.
  • Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • GWQ ServicePlus AG, Gesellschaft für Wirtschaftlichkeit und Qualität bei Krankenkassen, Düsseldorf, Germany.
  • SmartStep Data Institute GmbH, Hamburg, Germany.

Zitieren

APA

Wartmann, H., Hoffmann, S., Ruck, T., Nelke, C., Deiters, B., & Volmer, T. (2023). Incidence, Prevalence, Hospitalization Rates, and Treatment Patterns in Myasthenia Gravis: A 10-Year Real-World Data Analysis of German Claims Data. Neuroepidemiology. https://doi.org/10.1159/000529583

Vancouver

Wartmann H, Hoffmann S, Ruck T, Nelke C, Deiters B, Volmer T. Incidence, Prevalence, Hospitalization Rates, and Treatment Patterns in Myasthenia Gravis: A 10-Year Real-World Data Analysis of German Claims Data. Neuroepidemiology. 2023. doi:10.1159/000529583

BibTeX
@article{Wartmann2023,
  author = {Wartmann, Hannes and Hoffmann, Sarah and Ruck, Tobias and Nelke, Christopher and Deiters, Barthold and Volmer, Timm},
  title = {Incidence, Prevalence, Hospitalization Rates, and Treatment Patterns in Myasthenia Gravis: A 10-Year Real-World Data Analysis of German Claims Data},
  journal = {Neuroepidemiology},
  year = {2023},
  doi = {10.1159/000529583}
}
Kostenlos starten →